Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Shares Repurchased (2018 - 2025)

Corcept Therapeutics (CORT) has disclosed Shares Repurchased for 6 consecutive years, with $42.5 million as the latest value for Q3 2025.

  • For Q3 2025, Shares Repurchased rose 263.25% year-over-year to $42.5 million; the TTM value through Mar 2026 reached $145.5 million, up 241.28%, while the annual FY2025 figure was $172.9 million, 1003.9% up from the prior year.
  • Shares Repurchased hit $42.5 million in Q3 2025 for Corcept Therapeutics, down from $103.0 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $119.0 million in Q4 2021 and bottomed at $476000.0 in Q1 2024.
  • Average Shares Repurchased over 3 years is $39.6 million, with a median of $28.3 million recorded in 2021.
  • Year-over-year, Shares Repurchased surged 43378.18% in 2021 and then soared 263.25% in 2025.
  • Corcept Therapeutics' Shares Repurchased stood at $119.0 million in 2021, then crashed by 90.17% to $11.7 million in 2024, then skyrocketed by 263.25% to $42.5 million in 2025.
  • According to Business Quant data, Shares Repurchased over the past three periods came in at $42.5 million, $103.0 million, and $27.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.